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Abstract: Evidence of synergic health effects of co-supplementation with vitamin D and probiotics
is emerging. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PRISMA statement, scientific databases and the grey literature were searched, and a narrative review
and risk of bias assessment were conducted. Seven randomized controlled trials were included, which
had low risk of bias. Six studies were double-blind, and once single-blind, extended over 6–12 weeks,
and included 50–105 participants. Conditions explored included schizophrenia, gestational diabetes,
type 2 diabetes and coronary heart disease, polycystic ovarian syndrome, osteopenia, irritable bowel
syndrome (IBS), and infantile colic. Supplementation frequency was daily or bi-monthly, with
mainly vitamin D3, and Lactobacillus, Bifidobacterium, and Streptococcus. Comparators were placebo,
vitamin D, lower vitamin D dose, and probiotics and lower vitamin D dose. The co-supplementation
yielded greater health benefits than its comparators did in all studies except in one assessing IBS.
Beneficial effects included decreased disease severity, improved mental health, metabolic parameters,
mainly insulin sensitivity, dyslipidemia, inflammation, and antioxidative capacity, and lower use of
healthcare. Co-supplementation of vitamin D and probiotics generated greater health benefits than its
comparators did. More studies in other diseases and various populations are needed to confirm these
findings and to elucidate the optimal form, composition, and frequency of this co-supplementation.
Keywords: vitamin D; probiotic; supplementation; adults; randomized controlled trial; systematic review
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1. Introduction
The gut microbiota refers to the assemblage of microorganisms, including bacteria,
viruses, and fungi, located in the gastrointestinal (GI) tract [1]. There has been increasing
emphasis on the role of the microbiota in physiology, suggesting that it can be considered
as another human organ [2]. Furthermore, emerging evidence suggests that this invisible
organ is a key driver of human health and disease. Gut microbiota plays a critical role in
maintaining metabolic and immune health, synthesis of vitamins, obtaining inaccessible
nutrients from the diet, renewal of epithelial cells, fat storage, maintaining intestinal barrier integrity, and brain development [3,4]. Dysbiosis, or alteration in the gut microbiota
composition, is a crucial risk factor for the development of several disorders such as inflammatory bowel disease, obesity, diabetes, asthma, and allergies [5,6]. The gut microbiota
composition is affected by intrinsic and extrinsic factors like genetics, age, dietary changes,
in addition to physiological and psychological stress [2,7].
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Specifically, vitamin D and the vitamin D receptor (VDR) were shown to modulate the gut microbiota [8]. Increased VDR expression may decrease microbial dysbiosis, enhance barrier function, increase the expression of antimicrobial peptides, decrease
pro-inflammatory cytokines, and increase the commensal production of short-chain fatty
acids [2,8]. Likewise, probiotics, which are ingestible nonpathogenic living microorganisms,
were also shown to improve the balance of intestinal microbiota by regulating microbial
components and metabolites [9]. Probiotics simulate the immune system, balance commensal and pathogenic bacteria, and reestablish homeostasis. They protect barrier integrity,
alter toxic compounds, and host products. Thus, they ameliorate inflammation and prevent
and repair cell damage [9].
Vitamin D deficiency and defects in VDR signaling have been related to several
metabolic, cardiovascular, neurodevelopmental and cancer diseases [10,11]. Yet, interventional studies have conflicting evidence on the effect of vitamin D supplementation in
their treatment [12–16]. Similarly, human probiotic supplementation studies generated
conflicting evidence regarding the effectiveness of probiotics in the treatment of several
health conditions such as allergies, GI disorders, metabolic syndrome, and obesity [17–20].
Recently, a promising evidence of synergic effects of combined supplementation with
vitamin D and probiotics in modulating the gut microbiota and metabolome, in addition to
fostering healthy microbe–host interactions, is emerging [9,21,22]. This co-supplementation
holds a preventive and therapeutic potential with crucial clinical implications. Biologically
plausible mechanisms support this interplay. Probiotics were shown to increase vitamin D
intestinal absorption, and increase VDR protein expression and transcriptional activity [9].
Likewise, VDR status seems to be crucial in regulating the mechanisms of action of probiotics and modulating their anti-inflammatory, immunomodulatory and anti-infective
benefits, suggesting a two-sided pathway [6,8].
The aim of this systematic review is to investigate the literature and summarize the
available evidence of randomized controlled trials (RCTs) on the various health effects of a
combined supplementation of vitamin D and probiotics among children and adults.
2. Materials and Methods
2.1. Review Design
The reporting of this systematic review followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement [23]. A predefined protocol
for this systematic review was registered at the OSF registries.
2.2. Criteria for Study Inclusion
Randomized controlled trials (RCTs) conducted on adults or children, healthy or with
disease other than those known to influence vitamin D metabolism, and including an
intervention group that received a co-supplementation of vitamin D and probiotics, and a
control group of placebo, or a lower dose of vitamin D or probiotics, or a different form
of vitamin D, or different strains of probiotics, were included in this systematic review.
RCTs with a duration of a minimum of 1 month were included; this duration was deemed
sufficient for the intervention to produce an effect. Additionally, RCTs involving other
co-interventions were included, only if both arms received the same co-intervention.
Studies were excluded if they were non-randomized, uncontrolled, involving participants taking medication known to influence vitamin D metabolism or with conditions
affecting vitamin D metabolism such as chronic kidney disease, chronic liver disease, or
malabsorption states, or entailing a supplementation with either vitamin D or probiotics.
2.3. Search Strategy
The systematic search included Medical Subject Headings (MeSH) and keywords
for three concepts: (1) vitamin D, (2) probiotics, and (3) randomized controlled trial,
and was conducted in PubMed, MEDLINE, CINAHL, EMBASE, the Cochrane Library,
ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP), from
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inception until 4 November 2020, without language restrictions. The electronic search
strategy, detailed in the Tables S1 and S2, was validated by a medical information specialist.
Reference lists of included RCTs and relevant reviews were also hand-searched for eligible
studies.
2.4. Study Selection
The titles and/or abstracts retrieved by the search were screened by two pairs of
authors, and the full text of all relevant papers was assessed for eligibility independently
and in duplicate. A calibration exercise was conducted before study selection to ensure the
validity of the process. Inconsistencies were discussed amongst reviewers, and unresolved
discrepancies were settled by a third reviewer.
2.5. Data Extraction
Data from the selected articles were extracted by two pairs of authors using a data
extraction form. Changes from baseline for the intervention were compared with the control
in all the parameters analyzed. A calibration exercise was first conducted. Disagreements
were resolved through discussion or with the help of a third reviewer.
2.6. Quality Assessment
The risk of bias for the included studies was assessed using the Cochrane criteria
(sequence generation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data, and selective outcome reporting) [24], whereby each
potential source of bias was graded as low, high, or unclear risk. The process was carried
out by two pairs of authors independently and in duplicate. They underwent a calibration
exercise before performing the assessment of risk of bias. Conflicts were resolved through
discussion amongst the pair of reviewers or through consultation with a third reviewer.
2.7. Data Synthesis
A narrative review of the findings was performed and is included in Table S2.
3. Results
3.1. Search Results
Study selection process is detailed in Figure 1, whereby seven studies meeting the
inclusion criteria were included in the systematic review.
3.2. Characteristics of Included Studies
Characteristics of included RCTs are detailed in Table 1. The studies were published
between 2015 [25,26] and 2019 [27,28]. Five studies were conducted in Iran [27–31], one in
Italy [25], and one in the United Kingdom [26]. All the studies were randomized doubleblind [26–31], except for Savino et al. [25], which was single-blind. The duration of the
studies ranged between 6 [29,31] to 12 weeks [25–28,30]. The number of participants
ranged between 50 [31] and 105 [25]. The studies were conducted on infants [25], pregnant
women [29], and other adults with diseases [26–28,30,31]. Health conditions that were studied included schizophrenia [27], gestational diabetes mellitus (GDM) [29], type 2 diabetes
mellitus (T2DM) and coronary heart disease (CHD) [30], polycystic ovarian syndrome
(PCOS) [28], osteopenia [31], irritable bowel syndrome [26], and infantile colic [25].
In the studies by Ghaderi et al. [27], Ostadmohammadi et al. [28], Raygan et al. [30]
interventions consisted of a co-supplementation with vitamin D and probiotics, and the
control group received placebo only [27,28,30]. In the study by Tazzyman et al. [26], the
intervention group received a co-supplementation with vitamin D and probiotics, one of
the control groups received a placebo, and the other one received placebo and vitamin
D [26]. In Savino et al. [25], the intervention group received vitamin D and probiotics,
but the control group received vitamin D only. In the study by Jafarnejad et al. [31], the
intervention group received probiotics, yet vitamin D was supplemented in all groups.
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This co-intervention rendered the comparison between the intervention group receiving
probiotics and vitamin D and the control group receiving placebo and a similar dose of
vitamin D. Additionally, in the study by Jamilian et al. [29] the intervention consisted of
a co-supplementation with vitamin D and probiotics; one of the control groups received
probiotics, and the other one received placebo. Yet, in this study [29], all the groups also
received a lower dose of vitamin D. This co-intervention rendered the comparison between
the intervention group receiving probiotics and a high dose of vitamin D, the first control
group receiving probiotics and a lower dose of vitamin D, and the second control group
receiving placebo and a lower dose of vitamin D [29].

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Diagram of Study Selection.
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Table 1. Characteristics of included studies.
First Author,
Year, Country

Study Design

Ghaderi, 2019,
Iran [27]

Randomized,
double-blind,
placebo-controlled
trial

Jafarnejad,
2017, Iran [31]

Randomized,
double-blind,
placebo-controlled
clinical trial

Duration

Study Population

12 weeks

n = 60, aged 25–65, 93.33% men,
diagnosed with schizophrenia using
DSM-IV-TR criteria with disease
duration ≥2 years, PANSS score ≥55,
treated with chlorpromazine
(300–1000 mg/day, except clozapine) and
anticholinergic agents (Trihexyphenidyl,
4–8 mg/day) during the last 6 months

6 weeks

n = 50, age 50–72 years, women with
mild bone loss (osteopenia) diagnosed
based on the World Health Organization
criteria (T-score between −1.0 and −2.5)

Intervention

Control

Co-Intervention

Compliance/Drop-out

Placebo similar shape
and packaging

None

Compliance:
>90%Drop out:
I: 13.33%
C: 13.33%
(Intention-to-treat
analysis)

Placebo similar in shape,
size, odor, color and
packaging

Vitamin D (200 IU daily)
and Calcium
(500 mg daily)

Compliance 100%
Drop out:
I: 20%
C: 16%

C1: 8 × 109 CFU/day of
probiotic supplements
C2: Placebo
Similar in appearance,
color, shape, size, odor,
taste and packaging

Vitamin D3: 1000 IU and
Vitamin B9: 400 mg, daily
from the beginning of
pregnancy, and Ferrous
sulfate: 60 mg, daily from
the secondtrimester

Compliance: 100%
Drop out:
I: 0%
C1: 6.66%
C2: 10%

Placebo similar in
appearance, color, shape,
size, odor, taste and
packaging

None

Compliance 100%; No
drop out

None

Compliance > 90%
Drop out:
I: 13.33%
C: 13.33%
(Intention-to-treat
analysis)

Vitamin D3 and probiotic supplement:
-

Vitamin D3: 50,000 IU every 2 weeks;
DDE = 3571.4 IU
Probiotics: 8 × 109 CFU/day containing
Lactobacillus acidophilus, Bifidobacterium bifidum,
Lactobacillus reuteri, and Lactobacillus fermentum
(each 2 × 109 CFU/day)
Probiotic supplement: Lactobacillus casei 1.3 × 1010 CFU,
Bifidobacterium longum 5 × 1010 CFU, Lactobacillus
acidophilus 1.5 × 1010 CFU, Lactobacillus rhamnosus
3.5 × 109 CFU, Lactobacillus bulgaricus 2.5 × 108 CFU,
Bifidobacterium breve 1 × 1010 CFU, and Streptococcus
thermophilus 1.5 × 108 CFU/500 mg

Vitamin D and probiotic supplement:

Jamilian, 2018,
Iran [29]

Randomized,
double-blind,
placebo-controlled
clinical trial

6 weeks

n = 87, women with GDM diagnosed by
a “one-step” 2-h 75-g oral glucose
tolerance test based on the ADA
guidelines

-

Vitamin D: 50,000 IU every 2 weeks;
DDE = 3571.4 IU
Probiotics: 8 × 109 CFU/g probiotic containing
Lactobacillus acidophilus, Bifidobacterium bifidum, L.
reuteri, and Lactobacillus fermentum
(each 2 × 109 CFU/g)

Vitamin D and probiotic supplement:
Randomized,
Ostadmohammadi,
double-blind,
2019, Iran [28]
placebo-controlled
clinical trial

12 weeks

n = 60, aged 18–40 years, women with
PCOS, diagnosed based on the
Rotterdam criteria with BMI:
17–34 kg/m2 and insulin resistance: 1.4–4

-

Vitamin D: 50,000 IU every 2 weeks;
DDE = 3571.4 IU
Probiotics: 8 × 109 CFU/day containing
Lactobacillus acidophilus, Bifidobacterium bifidum,
Lactobacillus reuteri and Lactobacillus fermentum
(each 2 × 109 CFU/g)

Vitamin D3 and probiotic supplement:

Raygan, 2018,
Iran [30]

Randomized,
double-blind,
placebo-controlled
clinical trial

12 weeks

n = 60, age 45–85 years, 50% men, with
T2DM diagnosed based on the criteria of
the ADA and with CHD diagnosed as
per the AHA with 2- and 3-vessel CHD

-

Vitamin D3: 50,000 IU every 2 weeks;
DDE = 3571.4 IU
Probiotics: 8 × 109 CFU/g
containing Lactobacillus acidophilus, Bifidobacterium
bifidum, Lactobacillus reuteri, and Lactobacillus
fermentum (each 2 × 109 CFU/g)

Placebo similar in
appearance, color, shape,
size, odor, taste and
packaging
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Table 1. Cont.
First Author,
Year, Country

Study Design

Savino, 2015,
Italy [25]

Single-blind,
randomized
controlled,
parallel-group trial

Duration

Study Population

12 weeks

n = 105, newborns aged less than 10 days
of life, 48.5% boys, with gestational age
between 37 and 42 weeks, birth weight
from 2500 to 4300 g, and normal physical
examination

12 weeks

n = 51, 7.8% men, with previous clinical
diagnosis of IBS and met the Rome III
criteria and stratified according to
vitamin D status at baseline (deficient:
25(OH)D <20 ng/mL; repleted: 25(OH)D
>20 ng/mL)

Intervention

Control

Co-Intervention

Compliance/Drop-out

Vitamin D (400 IU daily)

None

No infants lost to
follow- ups

C1: Double placebo
C2: Placebo and Vitamin
D3 (400 IU daily)
Similar in form,
containing identical
buffers

None

Compliance: 98%
Drop out: 0%

Vitamin D and probiotic supplement:
-

Vitamin D3: 400 IU daily
Probiotics: Lactobacillus reuteri DSM 17938
(108 CFU)

Vitamin D3 and probiotic supplement:
Tazzyman,
2015, United
Kingdom [26]

Double-blind,
randomized,
three-arm parallel
design trial

-

Vitamin D3: sublingual liquid spray, 3000 IU daily
Probiotics: Lactobacillus acidophilus, CUL60
(NCIMB 30157), CUL21 (NCIMB 30156),
Bifidobacterium bifidum CUL20 (NCIMB 30153) and
Bifidobacterium animalis subsp. lactis CUL34
(NCIMB 30172) 2.5 × 1010 CFU per capsule

25(OH)D: 25-hydroxyvitamin D; ADA: American Diabetes Association; AHA: American Heart Association; BMI: Body Mass Index; C: Control; CFU: Colony Forming Units; CHD: Coronary Heart Disease; DDE:
Daily Dose Equivalent; DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; GDM: Gestational Diabetes Mellitus; I: Intervention; IBS: Irritable Bowel Syndrome; IU:
International Unit; PANSS: The Positive and Negative Syndrome Scale; PCOS: Polycystic Ovary Syndrome; T2DM: Type 2 Diabetes Mellitus; TDD: Total Daily Dose.
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The frequency of supplement administration ranged between daily [25,26,31] and
bi-monthly [27–30]. Probiotic supplementation was given in the form of a capsule in
all studies [25–31], whereas supplementation of vitamin D was either in the form of a
capsule [26–31] or sublingual liquid spray [25]. The form of vitamin D supplemented
was not specified in the studies by Jamilian et al. [29], Ostadmohammadi et al. [28], and
Jafarnejad et al. [31], and studies by Ghaderi et al. [27], Raygan et al. [30], Tazzyman
et al. [26], and Savino et al. [25] used vitamin D3, and the daily dose equivalent ranged from
200 International Units (IU) [31] to 4571.4 IU [29]. Probiotic strains that were investigated
included Lactobacillus in all the studies [25–31], Bifidobacterium in all the studies [26–31]
except for the one by Savino et al. [25], and Streptococcus only in Jafarnejad et al. [31].
The supplemented doses greatly varied across studies, and in the majority of the studies,
it consisted of 8 × 109 Colony Forming Units (CFU) per day.
There was a high rate of compliance in all studies [25–31], and the drop-out rate
ranged from 0% [25,26,28,29] to 20% [31], and was almost equal between the compared
groups in all studies [25–28,30,31], except in Jamilian et al. [29].
3.3. Assessment of Risk of Bias
Risk of bias assessment of included RCTs is available in Table 2. In general, the quality
of the RCTs design and reporting was high. In all studies [25–31], random allocation of
participants was adequate, and allocation was concealed. Blinding of participants and
personnel was reported in all of the included studies [26–31], except in the one by Saviano
et al. [25], where both patients and physicians, except outcome assessors, were aware of
their allocation. All studies reported complete outcome data [25,26,28,29,31], except for
the studies conducted by Ghaderi et al. [27] and Raygan et al. [30] who did not mention
how missing data were dealt with. Finally, in all studies [25–31], all pre-specified outcomes
were reported on.
Table 2. Risk of bias of included studies from consensus between a pair of raters.

First Author,
YEAR

Random
Sequence
Generation
(Selection
Bias)

Allocation
Concealment
(Selection
Bias)

Blinding of
Participants
and Personnel
(Performance
Bias)

Blinding of
Outcome
Assessment
(Detection
Bias)

Incomplete
Outcome
Data
(Attrition
Bias)

Selective
Reporting
(Reporting
Bias)

Other
Bias

Ghaderi, 2019
[27]
Jafarnejad, 2017
[31]
Jamilian, 2018
[29]
Ostadmohammadi,
2019 [28]
Raygan, 2018
[30]
Savino, 2015 [25]
Tazzyman, 2015
[26]
Low risk of bias

Unclear risk of bias

High risk of bias.

3.4. Results of Included Studies
The outcomes assessed and the findings of included RCTs are presented in Table 3.
In Ghaderi et al. [27], Ostadmohammadi et al. [28], Raygan et al. [30], and Savino et al. [25],
co-supplementation with probiotics and vitamin D yielded greater health benefits than
either placebo [27,28,30] or vitamin D on its own [25]. Specifically, in Ghaderi et al. [27], the
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co-supplementation, compared with placebo, had a favorable effect on schizophrenia symptoms severity, as well as other metabolic outcomes, mainly insulin sensitivity, inflammation,
and antioxidative capacity. In Ostadmohammadi et al. [28], vitamin D and probiotic cosupplementation in women with PCOS, compared with placebo, had beneficial effects on
mental health parameters, namely depression, anxiety and stress, as well as hormonal,
inflammatory, and antioxidative parameters, and on the symptoms of PCOS, specifically,
hirsutism. However, the co-supplementation was not associated with improvements in sex
hormone-binding globulin, nor with other symptoms of PCOS, namely acne and alopecia,
nor were there improvement in sleep quality [28]. In Raygan et al. [30], combined supplementation with vitamin D and probiotics for people with T2DM and CHD, compared
with placebo, improved anxiety and depression, insulin sensitivity, inflammatory markers,
antioxidative capacity and dyslipidemia, specifically high-density lipoprotein-cholesterol.
However, this intervention did not result in a better control of fasting glucose, other markers of dyslipidemia, specifically triglycerides, very low and low lipoprotein-cholesterol,
nor with blood pressures [30]. In the study by Savino et al. [25], compared with vitamin
D supplementation alone, vitamin D and probiotic co-supplementation to newborns was
associated with a reduction of more than two pediatric consultations and phone calls regarding infantile colic over a 12-week period. The co-supplementation was also associated
with a lower use of pain-relieving agents and of infant formula [25].
In the study by Jamilian et al. [29], all women with GDM in all groups were being
supplemented with 1000 IU (low dose) vitamin D. The group supplemented with probiotics
and high dose vitamin D, compared with placebo and low dose vitamin D, showed greater
improvement in glucose control, insulin sensitivity, dyslipidemia, inflammatory markers,
and antioxidative capacity [29]. Additionally, upon birth, newborns of mothers in this arm
had lower incidence of both hyperbilirubinemia and hospitalization [29]. Moreover, the
group supplemented with probiotics and high dose vitamin D, compared with probiotics
and low dose vitamin D, exhibited a greater improvement in dyslipidemia, inflammation
and antioxidative capacity [29]. Furthermore, newborns had better health outcomes [29].
Similarly, in the study by Jafarnejad et al. [31], all groups received 200 IU of vitamin
D, and the group receiving probiotics had improvement in osteopenia markers (bone
resorption and turnover), namely, bone-specific alkaline phosphatase, collagen type 1 crosslinked C-telopeptide, tumor necrosis factor α, and parathyroid hormone, but did not show
an improvement in bone mineral density nor other serum indicators of osteopenia [31],
compared with the group receiving placebo and vitamin D.
The only study where the co-supplementation was not found to be more effective
than its comparators was the one conducted by Tazzyman et al. [26], where no significant
difference in the symptoms of irritable bowel syndrome (IBS) was evident, between cosupplementation with probiotics and vitamin D, compared with vitamin D alone, or
with placebo.
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Table 3. Outcomes and results of included studies.
First Author,
Year, Country

Outcome Measures

Results

Conclusion

Ghaderi, 2019,
Iran 1 [27]

BMI: weight in kg divided by height in meters squared (height and weight
measured withoutshoes and in light clothing by a trained staff)
Serum 25-hydroxyvitamin D: ELISA kit
Severity of psychiatric symptoms: PANSS
Domains of cognitive function: BPRS scores
TAC: method of ferric reduction antioxidant power developed by Benzie
and Strain
GSH: Beutler method
MDA: Thiobarbituric acid reactive substances spectrophotometric Test
Serum hs-CRP: ELISA kit
NO: Griess Method
Serum insulin: ELISA kit
HOMA-IR and QUICKI: calculated using standard formula
FPG and lipid profiles: Enzymatic kits

At baseline and end line: No significant difference between-groups, in height,
age, weight, BMI and METs
At baseline: Significant difference between-groups for positive PANSS score,
BPRS, GSH and plasma NO
At end line:
In the I group compared with the C group:
Significant greater decrease in MDA (−0.3 ± 0.9 vs. +0.2 ± 0.4 µmol/L), serum
hs-CRP (−2.3 ± 3.0 vs. −0.3 ± 0.8 mg/L), FPG (−7.0 ± 9.9 vs.
−0.2 ± 9.9 mg/dL), serum insulin (−2.7 ± 2.3 vs. +0.4 ± 2.0 µIU/mL),
HOMA-IR (−0.8 ± 0.7 vs. + 0.1 ± 0.7), TG (−7.8 ± 25.2 vs. +10.1 ± 30.8 mg/dL),
TC (−4.9 ± 15.0 vs. +5.9 ± 19.5 mg/dL), and TC/HDL-C (−0.1 ±0.6 vs.
+0.3 ± 0.8)
Significant greater increase in 25-hydroxyvitamin D (+9.1 ± 4.1 vs.
+0.2 ± 0.4 ng/mL), general PANSS score (−3.1 ± 4.7 vs. +0.3 ± 3.9), total PANSS
score (−7.4 ± 8.7 vs. −1.9 ± 7.5), plasma TAC (+51.1 ± 129.7 vs.
−20.7 ± 53.3 mmol/L), QUICKI (+0.02 ± 0.01 vs. +0.0003 ± 0.01)
No significant difference in the change of BPRS score and other metabolic
profilesIn the analysis adjusting for baseline values of biochemical parameters,
age and BMI, and controlling for potential confounders:
The difference in changes in TC/HDL between the two groups became
non-significant
The difference in changes in negative PANSS score, BPRS and plasma GSH
became statistically significant
Other metabolic profiles did not change statically

Probiotic and vitamin D
co-supplementation for 12 weeks
to patients with chronic
schizophrenia had beneficial
effects on the general and
total PANSS scores, as well as
their metabolic profiles,
compared with placebo

Jafarnejad,
2017, Iran [31]

Nutrient intake: 3-day dietary recall (2 weekdays and one weekend day),
through monthly interview throughout the study period; nutrient analysis: by
Nutritionist IV software modified for Iranian foods
Physical activity: daily physical activity questionnaires validated by Kelishady
et al. and calculated as metabolic equivalents/day
Body weight: measured wearing light clothes without shoes using digital
scales with 100-g precision
Height: measured using a stadiometer with 0.5-cm precision in a normal
standing position without shoes.
BMI: weight in kilograms divided by height in meters squared
BMD: dual energy X-ray absorptiometry
Bone and pro-inflammatory biomarkers (TNF-α and IL-1b), Total serum levels
of BALP, Osteocalcin, CTX, Vitamin D, RANKL, Osteoprotegrin, Serum TNF-α
and IL-1b, Serum PTH, Urinary deoxypyridinoline: ELISA kits
Serum calcium, phosphorus, magnesium, albumin, creatinine, alkaline
phosphatase, and urinary amounts of calcium, phosphorus, magnesium, and
creatinine: Pars Azmoon kits

At baseline: No significant differences between-groups
At end line:
Significant between-group differences in
BALP (U/L) (I: 19.65 ± 1.66 at baseline and 16.53 ± 0.90 at end line vs. C:
17.81 ± 1.35 at baseline and 18.63 ± 1.29 at end line); CTX (ng/mL) (I: 0.41 ± 0.02
at baseline and 0.35 ± 0.02 at end line vs. C: 0.45 ± 0.02 at baseline and
0.42 ± 0.02 at end line); TNF-α (pg/mL) (I: 4.24 ± 0.5 at baseline and 3.73 ± 0.43
at end line vs. 3.83 ± 0.47 at baseline and 4.32 ± 0.5 at end line); PTH (pg/mL) (I:
31.92 ± 1.39 at baseline and 29.05 ± 1.53 at end line vs. C: 30.65 ± 1.44 at baseline
and 32.81 ± 1.72 at end line)
No significant between-group difference in Spinal BMD, Total hip BMD, RANKL,
osteoprotegrin, RANKL/ osteoprotegrin ratio, deoxypyridinoline, osteocalcin,
IL-1, Vitamin D, serum calcium, 24-h urinary Calcium, Serum phosphorus, 24-h
urinary phosphorus, Serum magnesium, 24-h urinary magnesium, Serum
creatinine, 24-h urinary creatinine, ALP, Albumin

Supplementation with probiotics,
vitamin D and calcium for
6 weeks to postmenopausal
osteopenic women showed a
possible role in suppressing bone
resorption and bone turnover,
but did not affect bone density
and other serum indicators
compared with placebo, vitamin
D and calcium
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Table 3. Cont.
First Author,
Year, Country

Jamilian, 2018,
Iran 2,3 [29]

Outcome Measures

Results

Conclusion

BMI: weight in kg divided by height in meters squared (height and weight
measured withoutshoes and in light clothing by a trained staff)
Polyhydramnios: sonographic estimation method at post-intervention and
defined as an AFI in excess of 25 cm
Preterm delivery: defined as delivery occurred at <37 weeks of pregnancy
Newborn’s macrosomia: defined as birth weight of >4000 g. 2.5
Serum 25-hydroxyvitamin D: ELISA kit
Serum insulin: ELISA kit
HOMA-IR and QUICKI: calculated according to the standard formula
FPG, serum TG, VLDL-C, TC, LDL-C and HDL-C: enzymatic kits
Serum hs-CRP: ELISA kit
Plasma NO: Griess method
TAC: method of ferric reducing antioxidant power developed by Benzie
and Strain
GSH: Beutler method
MDA: Thiobarbituric acid reactive substances spectrophotometric Test
Newborns’ hyperbilirubinemia: when the total serum bilirubin levels were at
≥15 mg/dL (257 mmol/L) among infants 25–48 h old, 18 mg/dL (308 mmol/L)
in infants 49–72 h old, and 20 mg/dL (342 mmol/L) in infants >72 h old

At baseline and end line: No significant difference between-groups, in age,
height, weight, BMI, METs and intakes of macro- and micronutrients
At end line:
In the I group compared with the C1 group
Significant greater decrease in TG (β −15.82 mg/dL), VLDL-C (β −3.16 mg/dL)
and hs-CRP (β −0.32 mg/L)
Significant greater increase in serum 25-hydroxyvitamin D (β 16.16 ng/mL), TAC
(β 63.26 mmol/L) and GSH (β 53.61 mmol/L)Lower incidence of
hyperbilirubinemiain newborns (10.0% vs. 13.8%)
Lower incidence of newborns’ hospitalization (10.0% vs. 10.3%)
No significant changes in other pregnancy outcomes
In the I group compared with C2 group:
Significant greater decrease in FPG (β −10.99 mg/dL), serum insulin
(β −1.95 mIU/mL), HOMA-IR (β −0.76; 95%), TG (β −37.56 mg/dL), VLDL-C
(β −7.51 mg/dL), HDL/TC B: −0.52), hs-CRP (β −1.80 mg/L) and MDA
(β −0.43 mmol/L)
Significant greater increase in 25-hydroxyvitamin D (β 18.21 ng/mL), QUICKI
(β 0.01) HDL-C (β 4.09 mg/dL) and TAC (β 97.77 mmol/L)
No significant changes in other metabolic parameters
Lower incidence of hyperbilirubinemia in newborns (10.0% vs. 35.7%)
Lower incidence of newborns’ hospitalization (10.0% vs. 32.1%)
No significant changes in other pregnancy outcomes
In the C1 group compared with the C2 group
Significant greater decrease in FPG (β −8.60 mg/dL), Insulin (β −1.34 µIU/mL),
HOMA-IR (β −0.54), TG (β −21.73 mg/dL), VLDL-C (β −4.34 mg/dL) and
hs-CRP (β −1.36 mg/L), and MDA (β −0.50 µmol/L)
Significant greater increase in serum 25-hydroxyvitamin D (β 2.05 ng/mL)

High dose of vitamin D and
probiotic co-supplementation for
6 weeks to women with GDM
had beneficial effects on
metabolic status and newborns’
outcomes compared with
placebo and low dose of vitamin
D or probiotic supplementation
and a low dose of vitamin D

Hirsutism: mFG scoring system
Mental health: BDI, GHQ-28 and DASS
Quality of sleep: PSQI
Serum 25-hydroxyvitamin D: ELISA kit
Serum total testosterone and SHBG: ELISA kits
hs-CRP: ELISA kit
Plasma NO: Griess method
TAC: Benzie and Strain method
GSH: Beutler method
MDA: Thiobarbituric acid reactive substances spectrophotometric Test

At baseline:
No significant difference between-groups for mean age, height and dietary
macro- and micro-nutrient intakes.
At end line:
In the I group compared with the C group:
Significant greater decrease in BDI (β −0.58), GHQ (β − 0.93), DASS (β − 0.90),
total testosterone (β − 0.19 ng/mL), hirsutism (β − 0.95), hs-CRP
(β − 0.67 mg/L) and MDA (β − 0.25 µmol/L)
Significant greater increase in TAC (β 82.81 mmol/L) and GSH (β 40.42 µmol/L)
No significant effect on serum SHBG and plasma NO levels, acne, alopecia
and PSQI

Vitamin D and probiotic
co-supplementation for 12 weeks
to women with PCOS had
beneficial effects on mental
health parameters, but did not
affect serum SHBG, plasma NO
levels, acne, alopecia and PSQI,
compared with placebo

Ostadmohammadi,
2019, Iran 2,3
[28]
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Table 3. Cont.
First Author,
Year, Country

Outcome Measures

Results

Conclusion

Raygan, 2018,
Iran 1 [30]

Serum 25-hydroxyvitamin D: ELISA
FPG and lipid profiles: Enzymatic kit
Insulin: ELISA kit
HOMA-IR and QUICKI: standard formula
Hs-CRP: ELISA kit
Plasma TAC: Benzie and Strain method
GSH: Beutler and Gelbart method
MDA: spectrophotometric test
NO: Griess method
SBP and DBP: sphygmomanometer (Not detailed)
Mental health: BDI, BAI, GHQ-28

At baseline and end line:
No significant differences between-groups in mean age, height, weight, BMI and
METs and macro and micronutrient intakes
At end line:
In the I group compared with the C group:
Significant greater decrease in BDI (−2.8 ± 3.8 vs. −0.9 ± 2.1), BAI (−2.1 ± 2.3
vs. −0.8 ± 1.4) and GHQ scores (−3.9 ± 4.1 vs. −1.1 ± 3.4), Insulin (µIU/mL)
(−2.8 ± 3.8 vs. +0.2 ± 4.9), HOMA-IR (−1.0 ± 1.6 vs. −0.1 ± 1.5), and hs-CRP
(ng/mL) (−950.0 ± 1811.2 vs. +260.5 ± 2298.2)
Significant greater increase in 25-hydroxyvitamin D (ng/mL) (+11.8 ± 5.9 vs.
+0.1 ± 1.4), QUICKI (+0.03 ± 0.04 vs. −0.001 ± 0.01), serum HDL-cholesterol
(mg/dL) (+2.3 ± 3.5 vs. −0.5 ± 3.8), plasma NO (µmol/L) (+1.7 ± 4.0 vs.
−1.4 ± 6.7) and plasma TAC (mmol/L) (+12.6 ± 41.6 vs. −116.9 ± 324.2)
No significant different changes in FPG, Triglycerides, VLDL-Cholesterol,
LDL-Cholesterol, GSH, MDA, SBP and DBP

Vitamin D and probiotic
co-supplementation for 12 weeks
to diabetic people with CHD had
beneficial effects on mental
health, glycemic control,
HDL-cholesterol levels, hs-CRP,
NO and TAC, but did not affect
other metabolic profiles and
blood pressures, compared with
placebo

Savino, 2015,
Italy [25]

Administration of pain-relieving agents (cimetropium bromide at least three
times per week or simethicone at least five times per
week): daily reporting by parents
% of infants switching from exclusive breastfeeding to partial or exclusive
formula feeding: not detailed
Number of phone-calls and visits due to infantile colic: noted by the
pediatrician.

In the I group compared with the C group:

Tazzyman,
2015, United
Kingdom [26]

Serum 25(OH)D: Cobas e411 automated immunoassay
Dietary intake: Food frequency questionnaire analyzed using FETA open
source software
IBS symptom: questionnaire assessing abdominal pain (pain severity and
number of days with pain), bloating, bowel habits (minimum and maximum
bowel movement per day and satisfaction with bowel habit) and quality of life

Significantly lower use of pain-relieving agents: Cimetropium bromide:
RR: 0.04 (95%CI: 0.01–0.31); Simethicone: RR: 0.24 (95%CI: 0.14–0.41)
Significantly lower use of infant formula: RR: 0.37 (95%CI: 0.17–0.80)
Significantly lower number of calls to the pediatrician: 5.04 ± 2.64 vs.
8.40 ± 3.58
Significantly lower number of visits in the pediatric ambulatory: 2.66 ± 1.77
vs. 4.98 ± 1.89

Vitamin D and probiotic
co-supplementation for 12 weeks
to newborns was associated with
a reduction of pediatric
consultations for infantile colic,
use of pain-relieving agents and
of infant formula, compared with
vitamin D supplementation

At baseline: No significant differences between-groups
At end line:
In the I and C2 groups compared with the C1 group:
- Significantly higher 25OHD (ng/mL) (37.2 ±9.3 and 37.1 ± 11.7 vs. 25.3 ± 8.0)
No significant between-group differences for any symptom tested, and total
symptom severity (same results obtained for participants who were
25(OH)D-deficient at baseline)

Vitamin D and probiotic
co-supplementation had no
significant effect on the
symptoms of IBS, compared with
vitamin D alone, or placebo

-

25(OH)D: 25-hydroxyvitamin D; AFI: Amniotic Fluid Index; BAI: Beck Anxiety Inventory; BALP: Bone-Specific Alkaline Phosphatase; BDI: Beck Depression Inventory; BMD: Bone Mineral Density; BMI: Body
Mass Index; BPRS: Brief Psychiatric Rating Scale; C: Control; CHD: Coronary Heart Disease; CI: Confidence Interval; CXT: Collagen Type 1 Cross-Linked C-Telopeptide; DASS: Depression Anxiety and Stress
Scale; DBP: Diastolic Blood Pressure; ELISA: Enzyme-Linked Immunosorbent Assay; FBG: Fasting plasma glucose; GDM: Gestational Diabetes Mellitus; GHQ-28: General Health Questionnaire-28; GSH: Total
Glutathione; HDL-C: High-Density Lipoprotein Cholesterol; HOMA-IR: Homeostasis Model of Assessment-Insulin Resistance; hs-CRP: High-Sensitivity C-Reactive Protein; I: Intervention; IBS: Irritable Bowel
Syndrome; IL: Interleukin; LDL-C: Low-Density Lipoprotein Cholesterol; MDA: Malondialdehyde; MET: Metabolic Equivalent; mFG: modified Ferriman-Gallwey; NO: Nitric oxide; PCOS: Polycystic Ovary
Syndrome; PSQI: Pittsburgh Sleep Quality Index; PTH; Parathyroid Hormone; QUICKI: Quantitative Insulin Sensitivity Check Index; RANKL: Serum Total Receptor Activator of Nuclear Factor-kB Ligand; RR:
Relative Risk; SBP: Systolic Blood Pressure; SHGB: Sex Hormone-Binding Globulin; T2DM: Type 2 Diabetes Mellitus; TAC: Total Antioxidant Capacity; TC: Total cholesterol; TG: TNF: Tumor Necrosis Factor;
Triglycerides; VLDL-C: Very Low-Density Lipoprotein Cholesterol. 1 Significance obtained for the time × group interaction, computed by analysis of the one-way repeated measures ANOVA. 2 Outcome
measures refer to the change in values of measures of interest between baseline and end line in each group. 3 β: difference in the mean outcomes measures between treatment groups, and significance obtained
from multiple regression model (adjusted for baseline values of each variable).
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4. Discussion
So far, probiotic or vitamin D trials have shown major inconsistency in preventive or
therapeutic effects on various health outcomes. The emergence of promising experimental
studies on the interplay between vitamin D/VDR and probiotics in modulating the gut
microbiota and influencing health and disease has led to several clinical trials of a combined
supplementation in human subjects. Our exhaustive search identified seven eligible studies,
which were included in our review. Our results show that a combined supplementation
with vitamin D and probiotics was mostly more beneficial than placebo, vitamin D or
probiotics alone in improving health outcomes in various populations, and suggest a
dose-dependent effect.
Vitamin D deficiency had long been seen as a concern in metabolic and inflammatory
disorders [32–34]. In the included studies, the majority of inflammatory markers improved
with the co-supplementation. It is now evident that VDR expression regulates responses to
inflammation through numerous mechanisms, such as inhibiting the nuclear factor-kappa
B (NF-kB) pathway and activating autophagy [6]. VDR has an essential role for innate
immune cells in intestinal inflammation, whereby the deletion of VDR in macrophages and
granulocytes significantly increases the expression of pro-inflammatory cytokines in the
colon [35]. In contrast, VDR signaling stimulates anti-inflammatory cytokine secretion [36].
Being a transcription factor, VDR can regulate the expression and signaling of target genes
involved in intestinal inflammation and dysbiosis, such as Atg16l1 [6]. A genome-wide association study of the gut microbiota showed that VDR gene variation in humans influences
the intestinal microbiota [37]. Genetic variation at the VDR locus significantly influences
microbial co-metabolism and the gut–liver axis [37]. Another study in VDR knockout mice
found that the lack of VDR in the intestine leads to dysbiosis, with profound alterations in
the gut microbiome profile characterized by an increased abundance of Bacteroidaceae [38].
However, to date, the mechanisms behind the change of human VDR protein after using
vitamin D supplementation and its role in regulating the gut microbiome in health and
inflammation are not entirely known [6]. In parallel, the anti-inflammatory markers and
properties of probiotics are reliant on VDR expression [39]. There are data showing that
probiotic treatment enhances VDR expression and activity in the host. In a probiotic monoassociated pig model, treatment with Lactobacillus plantarum in cultured intestinal epithelial
cells resulted in an increase in VDR expression and cathelicidin mRNA [39]. Other data
show that probiotics did not inhibit inflammation in mice lacking VDR [39]. Future research
is needed to enhance our understanding of the complex interplay of nuclear receptors and
probiotics, specifically VDR’s contribution to probiotic-induced anti-inflammation and its
potential role in inflammatory conditions such as inflammatory bowel diseases [39].
Besides, our review documented improvement in insulin sensitivity, anti-oxidative
patterns, and dyslipidemia markers with co-supplementation of vitamin D and probiotics.
The same positive direction was also highlighted elsewhere [6,8]. Previous research documented a functional link existing between probiotic metabolism and nuclear receptors
involved in regulating insulin sensitivity [22]. In a mice model of genetic dyslipidemia and
intestinal inflammation, supplementation with a mixture of probiotic strains, including
Streptococcus thermophiles, Bifidobacterium breve, Bifidobacterium lactis, Lactobacillus acidophilus,
Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus helveticus modified the nuclear receptors’ expression including VDR, and caused their direct transactivation, leading
to reversing insulin resistance in liver and fat tissues and protecting against steatohepatitis
and atherosclerosis [40]. Yet, these results although emanating from high-quality studies,
are far from being conclusive, and future trials are needed before we can confidently
establish the effectiveness and superiority of this co-supplementation.
More human experimental studies are needed to fully elucidate the interplay between
nuclear receptors and probiotics in metabolic diseases. Shaping our understanding of this
unexplored path might pave the way for multi-target preventive and therapeutic strategies,
especially in situations where dietary and lifestyle changes have failed [22].
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Additionally, improvement in mental health has been reported in this review. Vitamin
D is involved in numerous brain processes including neuroimmunomodulation, neuroprotection, as well as brain development; all of which suggests a link between vitamin D and
mental health [41,42]. Vitamin D may positively affect mental health through up-regulating
tyrosine hydroxylase gene expression and increasing bioavailability of key neurotransmitters, such as norepinephrine and dopamine [43]. In parallel, mechanisms through which
gut bacteria can affect mental status include microflora biosynthesis and the regulation of
neurotransmitters, including serotonin [44] and gamma aminobutyric acid (GABA) [45].
Existing evidence also pinpoint an association between mood disorders and gut microbiota,
and specify a role of the gut–brain axis in the physiopathology of clinical depression [46].
It is highly plausible that the synergism in vitamin D and probiotics’ anti-inflammatory,
antioxidant, and immunomodulatory effects might augment their impact on mental health.
This is yet to be confirmed by future interventional human studies.
The only study in this review that reported null results with the co-supplementation
was a trial by Tazzyman et al. [26] which did not show any improvement in the symptoms
of patient with IBS whose vitamin D was repleted. This study had a limited sample size
(underpowered trial), and a limited duration of follow-up. Additionally, in that study,
the group receiving placebo showed an improvement in vitamin D levels, which might
be due to seasonal differences in sun exposure, and a placebo effect was observed on
symptom scores. The authors speculated that increased sunlight exposure had increased
vitamin D levels which in turn improved IBS symptoms. All of these limitations may
have prevented the authors from detecting a significant difference in symptom scores
between the placebo and supplemented groups. Additionally, individuals might need
higher doses of vitamin D plus probiotic supplementation for a longer period of time to
provide appropriate circulating levels for improving symptoms.
Understanding the mechanisms of the interplay between vitamin D and probiotics
in modulating the gut microbiota and regulating host responses, and exploring the effectiveness of this form of supplementation in high-quality human studies are crucial
before applying it to prevent and manage disease. Studies included in this review had
revealed thoroughly the superiority of co-supplementing with vitamin D and probiotics.
Vitamin D has shown benefits in cellular restoration and reducing inflammation. The latter
has been implicated in the pathophysiology of an unlimited number of conditions and
diseases. VDR expression and transcriptional activity can be a research focus for future
genetic studies. In parallel, data about probiotics and their role in optimizing microbiota
and absorption pathways would be very useful not only for vitamin D but for many other
nutrients or enzymes involved to boost immunity and host response.
5. Strengths and Limitations
To our knowledge, this is the first review to systematically compile human interventional evidence on the effectiveness of a combined supplementation of vitamin D
and probiotics. Our review has numerous strengths [47]. It was conducted following
standard methods for reporting systematic reviews [23], and according to a pre-defined
protocol, which was published a priori. To increase the comprehensiveness of our search,
we searched multiple scientific databases and the grey literature, and did not limit our
search to any publication language or time. All the steps of study inclusion, data extraction
and quality assessment were conducted in duplicate. We only included RCTs, and assessed
their risk of bias using a validated tool; and, in general, the included studies were of high
quality. However, included trials were limited in number, and conditions assessed. They
were also limited by the small sample size, and short duration of follow-up. Moreover, only
two studies [25,26] provided details regarding the strain of bacteria in the used probiotics.
None of the studies provided analyses of the gut microbiota, disabling us from establishing
whether the co-supplementation changed the composition of the microbiota, or ascertaining
whether the observed changes were due to changes in the gut microbiota. Furthermore, we
could not pool the studies in a meta-analysis due to the heterogeneity in the populations,
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conditions assessed, outcomes, doses and forms of vitamin D supplemented, and doses
and strains of probiotics supplemented.
6. Conclusions
A combined supplementation with vitamin D and probiotics seems to play a role on
the physiological and psychological attributes of the human body, and represents a novel
insight in the management of chronic diseases. The findings of this systematic review
suggest a superiority of vitamin D and probiotics supplementation over placebo, vitamin
D or probiotics alone, and propose a dose-dependent effect. However, solid conclusions
cannot be drawn at this level, and these findings remain certainly not robust enough and
should be interpreted with caution. Future high-quality studies in other disease areas
and various populations are needed to confirm these findings and to inform on the form,
composition, and frequency of this co-supplementation for optimal outcomes.
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